SecBot SecBot
8-K ·Filed Apr 24, 2026

NAMSW

NewAmsterdam Pharma Co N.V.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-177406
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor the next 10-Q filing for disclosure of the full separation agreement and any impact on compensation expenses. The departure of a financial officer warrants attention, but the orderly transition and lack of immediate replacement suggest a manageable transition.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.10
T+0 close · Apr 24, 2026 · via day close
Latest settled
+1.47%
T+60 · $19.38
Vs SPY
−3.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $19.10entry
  2. T+1 · 7mo ago 0.00%α +0.49% · $19.10
  3. T+5 · 7mo ago +11.15%α +10.75% · $21.23
  4. T+20 · 6mo ago +27.02%α +22.06% · $24.26
  5. T+60 · 4mo ago +1.47%α −3.31% · $19.38

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a separation agreement providing 12 months of base salary, a pro-rated bonus, and extended vesting of equity awards through January 2027. The departure appears planned and orderly.

Key Facts

  • Chief Accounting Officer Louise Kooij is departing effective August 31, 2026
  • Departure was mutually agreed upon and not unexpected
  • Separation agreement includes 12 months of base salary, pro-rated 2026 bonus, and accrued vacation
  • Equity vesting extended through January 10, 2027, with exercise period until February 10, 2027
  • No replacement has been announced

Financial Impact

Approximately 12 months of base salary plus pro-rated bonus (exact dollar amounts undisclosed)

cash flowcompensation expenseequity dilution

Risk Factors

  • Potential disruption in financial reporting during transition
  • Increased workload for remaining finance team
  • Uncertainty around succession planning for key financial roles

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-177406
Document: 0001193125-26-177406-index-headers.html0001193125-26-177406
Document: 0001193125-26-177406-index.html0001193125-26-177406
Document: 0001193125-26-177406.txt0001193125-26-177406

Track record

3 reports on NAMSW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 3, 202623w ago 8-K Neutral 3/10 Entry $24.90 to $16.51 Now $9.49 −61.88% ▼ −33.68% −36.18% vs SPY
  2. May 7, 202627w ago 8-K Bullish 6/10 Entry $22.80 to $15.00 Now $9.49 −58.38% ▼ −34.21% −38.04% vs SPY
  3. Apr 24, 202629w ago 8-K Neutral 3/10 Viewing Entry $19.10 to $19.38 Now $9.49 −50.31% ▲ +1.47% −3.31% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens in 7h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026